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ABSTRACT 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
 
Background: Diffuse large B cell lymphoma (DLBCL) is a heterogeneous group of B-cell 
lymphoma with variation in patient survival. Information regarding clinical presentation, 
staging, prognostic determinant (biological [GCB, non-GCB] and clinical[IPI]), and response 
to chemotherapy (CHOP and Rituximab CHOP) in exclusively nodal cases of DLBCL is 
limited.  
 
Aims and Objectives of the study:To analyse the response to chemotherapy (CHOP 
and Rituximab CHOP) and to access the prognostic significance of IPI and biological sub-
grouping  of nodal DLBCL cases in our institution. 
 
Methodology:All patients with nodal DLBCL cases who underwent treatment with 
minimum six months follow up in the Department of Haematology between January 2006 
and April 2010 and whose slides and blocks could be retrieved from Department of 
Pathology were included in the study. 
 
Results:Of the 106 patients, 71(67%) male and 78(73.6%) patients were <60 years of age. 
72(67.9%) presented with B-symptoms, 62(58.5%) had stage III/IV, and 80(75.5%) had high 
LDH at diagnosis. 22(20.8%) had one or more extra-nodal disease and 21(19.8%) had bulk 
disease. Out of 106 patients 66(62.2%) were in low IPI risk (0,1,2) and 40(37.7%) were in 
high IPI risk(3,4,5). Based on immune-histochemistry(Hanset.al) we classified 
43(40.5%)patients as GCB DLBCL and 63(59.4%) as non-GCB DLBCL. The clinical 
characteristics of patients in sub groups were similar.The CR+CRu was 88% in Rituximab vs 
70.9%% in non-Rituximab treated patients at the end of six cycles of chemotherapy 
(p=0.082). After a median follow up of 36 months (range:6-44months in RCHOP and 6-42 
months in CHOP),the  three year cumulative relapse free survival(RFS) and  overall 
survival(OS) was 56.4% and 74.5% respectively in those who  received CHOP 
chemotherapy. The addition of Rituximab improved the cumulative RFS and OS to 86.3% 
and 76.5% respectively, though the difference was not significant.  
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Addition of Rituximab in high IPI risk group patients, improve EFS and OS at 24 months to 
74.9% and 83.3% vs 19.8% and 41.5% in CHOP group(p=0.002). Rituximab treated patients 
in either GCB or non-GCB subgroup had similar EFS and cumulative RFS at median follow 
up of 24 months in comparison to non-Rituximab patients. In GCB group of patients the 
Rituximab significantly improves the OS (89.1%vs50.3%) at median follow up of 24 months 
(p=0.02). Neutropenia with or without fever was the most common chemotherapy related 
complication and was significantly more in RCHOP patients 68.6% vs 47.3%  (p=0.032). 
 
Conclusion:This is the largest series of patients with DLBCL comprehensively evaluated 
and analyzed for outcome after treatment with CHOP and RCHOP. Patients were classified 
into low and high IPI risk group as well GCB and non-GCB origin of their disease. Addition 
of Rituximab has significant advantage in GCB and high IPI risk subgroups. In non-GCB and 
IPI low risk sub group, Rituximab increases relapse free survival but not the overall survival. 
Further analysis needs to be done with more number of patients and longer follow-up to truly 
understand the trend observed in this study for patients in India. 
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INTRODUCTION 
 
 
 
 
Introduction 
Diffuse Large B cell Lymphoma (DLBCL) is a neoplasm of B cells of hematopoietic system. 
Approximately one-third of all adult lymphomas are DLBCL, the most commonly occurring 
form of non-Hodgkin lymphoma (NHL) in the western world and India1,2,3.DLBCL is 
associated with an aggressive natural history, with median survival of less than one year in 
untreated patients. The cyclophosphamide, doxorubicin, vincristine and prednisolone 
(CHOP) chemotherapy has been the mainstay of therapy for several decades (six years 
overall survival 33%), since more intensive chemotherapy were more toxic and failed to 
demonstrate additional benefits27,28.  
In largely separate efforts, remarkable progress has been made during the past decade in 
understanding the biological heterogeneity of DLBCL and improving survival for DLBCL 
patients with combination of CHOP and immunotherapy29.The integration of anti-lymphoma 
antibodies, notably rituximab®,into combination therapies for DLBCL have markedly 
improved patients outcomes across all subtypes32,33,34. Microarray analysis, gene expression 
profiling (GEP) has uncovered distinct molecular signatures for DLBCL subtypes that have 
distinct clinical behaviours and prognoses16,17,23. Various immune-histochemical algorithms 
have been developed to predict the almost similar results as GEP21,22. Most recently, 
molecular signatures identified through GEP not only contributed prognostic information, but 
also have aided the new therapeutic targets. There is very minimal data from India on 
DLBCL looking into the cell of origin based on immunohistochemical algorithm and 
comparing the response of therapy in different sub-type. 
The present study is a retrospective review of response of CHOP and RCHOP chemotherapy 
in nodal DLBCL cases classified based on immunomarkers into germinal cell (GCB) and 
non-germinal(non-GCB).  
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Review of literatures 
Introduction 
DLBCL is a neoplasm of large B lymphoid cells with nuclear size equal to or exceeding 
normal macrophage nuclei or more than twice the size of a normal lymphocyte that has a 
diffuse growth pattern. The WHO system modified DLBCL classification to recognize 
multiple morphologic variants based on improved understanding of the variety of molecular 
abnormalities associated with DLBCL8 (Table:1).  
Table:1World Health Organization Classification of Mature Large B-cell 
Neoplasm 
CLASSIFICATION 
Diffuse large B-cell lymphoma (DLBCL),NOS 
T-cell/histolytic rich large B-cell lymphoma 
Primary DLBCL of the CNS 
Primary cutaneous DLBCL,leg type 
EBV+ DLBCL of elderly 
DLBCL associated with chronic inflammation 
Lymphomatoidgranulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
ALK+ large B-cell lymphoma 
Plasmablastic lymphoma 
Large B-cell lymphoma arising in HHV8 associated multicentriccastleman disease 
Primary effusion lymphoma 
B-cell lymphoma,unclassifiable,with features intermediate between diffuse large B-cell lymphoma 
and Burkit lymphoma 
B-cell lymphoma,unclassifiable ,with features intermediate between diffuse large B-cell 
lymphoma and classical Hodgkin lymphoma 
 
 
 
Epidemiology 
Lymphomas are the fifth most common systemic cancer, with the most common subtype 
being diffuse large B-cell lymphoma followed by follicular lymphoma and Hodgkin 
lymphoma. DLBCL represents approximately 30% of all lymphomas and is the most 
common subtype throughout the world1,4. In two large epidemiological study the reported 
incidence in India is 34%2 and 59.3%3 respectively. It is more common in the elderly .The 
median age is in the 7th decade but it may also occur in children and young adults. It is 
slightly more common in males than in females1,2,3.The incidence of NHL increased 
dramatically from the 1970s until the middle of the 1990s with an estimated 65,540 new 
cases expected in the united states in 2010.Several factors have contributed to this increased 
incidence including : more sensitive methods for identifying diagnostic cases, improvement 
in cancers reporting for haematological malignancies, changes in the classification systems 
used for lymphoid malignancies, and the epidemic of  HIV infections occurring during this 
period with an associated increase in HIV-associated lymphomas5.For the majority of 
patients, the aetiology of DLBCL remain unknown. Some factors that influence the risk of 
lymphoma include genetics, co-morbid diseases or their treatments (notably 
immunosuppressant), environmental factors such as ultraviolet,pesticide ,hair dyes, and diet. 
A subset of DLBCL, including immune-blastic and primary central nervous system (CNS) 
disease, is highly associated with Epstein-Barr virus although, unlike certain indolent 
histologies, the concept of antigen driven lymphoma genesis is less developed in DLBCL6.   
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Clinical Presentation 
Most commonly patients present with a rapidly enlarging, painless lymph node in cervical, 
inguinal or axillary region. However in up to 40% of patients, the initially identified site is 
extra-nodal commonly involving the skin, gastrointestinal tract, central nervous system 
(CNS), lung, genitourinary tract or the bones7. Approximately 15% of the patients present 
with bone marrow involvement, about one-third have B-symptom (fever, night sweat, and 
weight loss),nearly one-half have Ann-Arbor system stage III/IV disease, and more than one 
half have an elevated serum lactate dehydrogenase (LDH)level5. 
 
Clinical Prognostic Factors 
Originally proposed in 1993,the international prognostic index(IPI) remains the primary 
clinical tool used to predict outcome for patients with DLBCL9.StageIII/IV disease, elevated 
LDH, age>60,Eastern Cooperative Oncology group(ECOG) performance status>2, and 
involvement of >1 extra-nodal site form the IPI score, with one point to each factor. The IPI 
scoring system nicely stratified patient into four groups with five years survival of 
73%,51%,43% and 26% for 0-1,2,3,4-5 risk factors res with CHOP based regimen9.However 
,the IPI was developed in the era before rituximab was routinely included in treatment 
regimen. To address this issue.Sehn and colleagues performed a population-based, 
retrospective, cohort analysis of 365 patients with newly diagnosed DLBCL treated with 
rituximab plus standard chemotherapy11. Although the IPI remained prognostic in this study, 
it no longer distinguished four outcome groups. With redistribution of the IPI factors into a 
Revised IPI(R-IPI) grouping.,3 separate categories were defined that provide more accurate 
prediction of outcome. Patients with zero risk factors had a >90% chance of 4-year 
 
 
progression free survival(PFS):those with 1-2 risk factors had >80% expected PFS;and those 
with >3 risk factors had >50% PFS11.  
Currently ,the original IPI remains as a prospectively designed and validated measure for 
assessing DLBCL risk12.  In 2007,the revised International Working Group response criteria 
for malignant lymphoma strongly recommended the use of PET scan for patients with 
routinely FDG-avid, potentially curable lymphoma such as DLBCL13,14 .The PET is 
recommended 1)Before treatment to better delineate the extent of disease13,14,2) six to eight 
weeks after completion of therapy for assessment of complete response(CR) because CR is 
required for cure in DLBCL13,14,and3) in the context of clinical trial mid treatment to evaluate 
the prognostic ability of interval PET to predict the ultimate response to therapy and long 
term outcome15. 
 
Biological Prognostic Factors 
To segregate DLBCL into biological meaningful subgroups that might identify rational 
therapeutic targets, the Leukemia and Lymphoma  Molecular Profiling Project began gene 
expression analyses of DLBCL biopsy sample by using DNA microarrays and identified 
biological  distinct and prognostically meaningful molecular subgroups of DLBCL16,17.The 
first group had a gene expression profile pattern clustered with normal germinal center B cell 
and was labeled as the GCB variants. The second group had a contrast set of signature genes 
similar to activated B cells, and thus was termed the ABC variant. The patients in GCB 
subgroup had a higher 5 year survival rate(60% vs 35%;P<.001)16,17. Molecular subtype had 
shown to predict survival independent of IPI risk17.Other biological markers including the 
antiapoptotic protein,Bcl-2, Bcl-6(a marker of germinal center derivation), and 
Myc(aprotoncogenetranscription factor) carry prognostic significance in DLBCL, and these 
are now being explored for interacting effects with ABC and GCB subtypes, PET scan 
 
 
imaging, and modern therapies18,19,20.Despite its usefulness, gene expression profiling 
technology has not moved easily into community practices.  
As a result, immune-histochemical algorithm have been proposed and validated for 
classification of DLBCL into GCB and non-GCB(ABC)21,22. (Fig:1) 
 
 
 
 
 
 
 
 
 
 
Fig:1 Immunohistochemistry based classification of DLBCL. 
 
An initial algorithm proposed by Hans et al21 used CD20,CD10,Bcl-6and MUM1(Fig:2) to 
distinguish GCB and non-GCB subtype(mostly ABC) with 86%  concordance with gene 
expression profiling. More recently ,a consortium of haemato-pathologist improved on Hans 
method by employing different immunostains, GCET1,CD10,BCL6,MUM1 and 
FOXP1(Fig:2) and derived a new algorithm with 93% concordance with gene expression 
profiling22. Sub-classification on the basis of cell of origin is predictive of survival in patients 
with DLBC; who were treated with Rituximab. In the GCB group significantly better overall 
survival(OS) and event free survival(EFS) than in the non-GCB subgroup(3 years OS 85% vs 
69% and 3 years EFS 67%vs 52%)23,24.Multivariate analysis has showed prognostic impact of 
the sub-classification on the basis of cell of origin on OS and EFS23,24.Multivariate analysis 
of the component of the IPI showed LDH is a significant predictor of both OS and EFS23.The 
expression of Bcl-2 and lack of expression of Bcl-6 associated with adverse outcome with 
CHOP chemotherapy but not with R-CHOP chemotherapy25,26. 
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Treatment and outcomes 
Newly diagnosed patient 
Although DLBCL is associated with a median survival of less than 1 year in untreated 
patients1,this disease is commonly curable with conventional anthracycline-based 
chemotherapy. Advances in the management of DLBCL during the last decade , including the 
advent of monoclonal antibodies have led to excellent outcomes for many patients. Until 
recently, the CHOP regimen developed in 1970s28, remained the standard therapy for 
DLBCL27,28. The Southwest Oncology Group(SWOG) and the Eastern Cooperative Oncology 
group(ECOG) ,prospective randomized  phase 3 trial that compared CHOP to three 
aggressive multi-agent regimen(m-BACOD,ProMACE/CytaBOM and MACOP-B) 
,concluded that the standard CHOP regimen produced similar survival outcome with less 
toxicity ( 6 years OS for CHOP regimen was 33% as compared to 36%,34%,and 32% 
respectively for other three regimens)27.In 1997 ,rituximab became the first monoclonal 
antibody approved for the use by US (FDA) for follicular lymphoma, and this 
immunotherapy was soon applied to DLBCL and other B-cell lymphomas29,30,31.  Groupe d’ 
Etude des Lymphomes de l’Adulte (GELA) study32,33,34 in 2002 compared R-CHOP with 
CHOP alone in patients older than 60 years, showed CR rates were significantly higher in 
patient who received R-CHOP than the group who received CHOP alone(76% vs 63%; 
P<.0005),and 2 year OS improved from 57% to 70%(P<.007)34.Updates of this trail 
demonstrated that the EFS,PFS and OS remained statistically significant in favors of R-
CHOP and actually continued to improve35. Results from the GELA trial were confirmed in a 
US Intergroup trial in older patients36. The benefits of rituximab in younger patients was 
addressed by Mab-Thera International  Trial(MInT),in which 824  patients were randomly 
 
 
assigned 6 cycles of rituximab CHOP or CHOP like chemotherapy or same chemotherapy 
alone. The three year EFS and OS were 79%vs59% and 93%vs 84% respectively, clearly 
better in rituximab group37.On the basis of above observations ,it is clear that rituximab 
containing regimen improve survival (EFS by 20% and OS by15%) for DLBCL patients 
regardless of age38.Among patients who presents with bulky disease, R-CHOP followed by 
radiation has been considered standard therapy38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relapsed patients 
Although the adoption of R-CHOP as the new standard of care has improved outcome for 
DLBCL, patients still relapse. A multicenter PARMA trail showed that in relapse group of 
patients two cycles of intensive chemotherapy followed by autologus stem cell 
transplant(ASCT) improves the EFS and OS(46%vs12% and 53%vs32%) in ASCT group 
than only chemotherapy group39,40.A recent evidence based review on the role of ASCT in 
the management of DLBCL continues to recommend ASCT as the salvage therapy for 
patients with chemo-sensitive relapsed DLBCL41.The choice of salvage chemotherapy after 
R-CHOP failure was addressed by prospective multicenter phase 3 study, the Collaborative 
Trail in Relapsed Aggressive Lymphoma(CORAL)43.DLBCL patients were randomized to 
receive salvage 3 cycles of R-ICE or R-DHAP followed by ASCT in the responders. The 
overall response rate(63.5%vs62.8%),3-year PFS(31%vs42%)and 3-year 
Oss(47%vs51.5%)for R-ICE and R-DHAP were not statistically different suggesting that 
either regimen can be used for salvage therapy42,43. Factors that affect 3-year OS include1) 
second line age adjusted IPI>2 (32%vs62%),2) relapse<12 months after completion of first 
line therapy (39%vs64%) and3) prior rituximab exposure in frontline setting 
(40%vs66%)41,42,43. 
 
 
 
 
 
 
 
 
Novel Therapies for DLBCL 
Although rituximab and R-chemotherapy regimens have greatly improved response rates and 
survival for patients with DLBCL, relapse remains a consistent clinical problem. Of 
particular concern are preliminary data from the CORAL trial indicating that although 
DLBCL is commonly cured with first-line R-CHOP, and many patients have been salvaged at 
relapse with ASCT in the past,41,42,43 current DLBCL patients are at higher risk when they 
relapse early following upfront R-CHOP chemotherapy and have a poor response to second-
line rituximab-containing regimens even when theseregimens are consolidated with high-
dose therapy and ASCT.42,43Novel approaches clearly are needed for DLBCL patients who 
relapse early after R-CHOP chemotherapy. These include other antibody therapies, 
lenalidomide51,52, SGN-40, bevacizumab, Syk inhibitors45 (fostamatinib disodium), 
enzastaurin50, histone deacetylase inhibitors, bortezomib47, antisurvivin agents, and mTOR 
inhibitors.44A multicenter clinical trial that uses the Hans method to subtype DLBCL patients 
and then randomizes non- GCB patients to bortezomib plus R-CHOP or RCHOP alone is 
now underway46,47,48.  Whereas rituximab was the first monoclonal antibody approved for B-
cell NHL and clearly has revolutionized therapy for DLBCL, other antibodies targeting B-
cell lymphomas are now available on an investigational basis, including AME-133, GA101, 
veltuzumab (all CD20), epratuzumab (CD22), dacetuzumab (CD40), galiximab (CD80), 
lexatumumab (TRAIL), as are other approaches to improve antibody therapy such as 
conjugation with radioisotopes or toxins53. Ultimately, understanding mechanisms by which 
malignant B-cells become resistant to rituximab and chemotherapy and determining means to 
address these mechanisms may provide pathways for approval of novel agents. Moreover, 
defining the biology of resistance and activity for various agents across DLBCL subtypes will 
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become increasingly important in the future as we attempt to select among regimens for 
newly diagnosed and relapsed patients. 
 
 
 
 
 
AIMS & 
OBJECTIVES 
 
 
 
AIMS AND OBJECTIVES 
1. To sub classify the Diffuse large B cell lymphoma (DLBCL) in two group   Germinal 
center(GCB) and non Germinal center(non-GCB) on the basis of expression of the 
three immunomarkersCD10, multiple myeloma oncogene 1 (MUM1), and polyclonal 
B-cell lymphoma 6 (BCL6)] . 
2. To ascertain biological and clinical presentation, staging and international prognostic   
index (IPI). 
3. To assess the response of chemotherapy (CHOP and  Rituximab CHOP) in DLBCL 
as whole and in two subgroup(GC, non GC). 
 
 
 
HYPOTHESIS 
1. Diffuse large B cell lymphoma sub-classification   based on Immuno-histochemical 
(IHC) stain algorithm on using formalin-fixed, paraffin-embedded tissues will 
correlates with historical data on gene expression profile. 
2. Cell based origin and sub-classification will have prognostic impact on overall 
survival and event free survival. 
3. The prognostic value of the DLBCL subgroup is statistically independent of the 
features included in the International Prognostic Indicator (IPI).  
4. Addition of Rituximab to standard chemotherapy improves the survival of patients 
with DLBCL, and in both GCB and non GCB group. 
 
 
 
 
 
 
 
PATIENTS AND 
METHODS 
 
 
 
PATIENTS AND METHODS 
This study protocol was approved by our Institutional Review Board (IRB). 
Duration of the Scheme: January 2006 to April 2010.  
Settings of the study: Department of Clinical Haematology, Department of Pathology 
Diagnostic criteria:  
Morphology:The involved tissue should fulfil the morphological description as per WHO 
2008(World Health Organization Classification of Mature Large B-cell Neoplasm): 
Infiltration of the tissue by large B lymphoid cells with nuclear size equal to or exceeding 
normal macrophage nuclei or more than twice the size of a normal lymphocyte that has a 
diffuse growth pattern.  
Immunomarkers: For Germinal center(GCB), nonGerminal centre(nonGCB) sub-
grouping. 
    Table:2                                                         Fig:2 
Markers Hans classifier*
CD20 POSITIVE 
CD3 REACTIVE T-Cells 
CD10 >30% 
BCL6 >30% 
MUM-1 >30% 
 
 
 
 
*.Christine P. Hans et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by 
immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282 
 
 
 
Table:3 Antibody used for Immunohistochemistry 
Antibody Clone Source Antigen Retrieval 
CD20 L26 DAKO Citrate(HIER) 
CD3 F7.2.38 DAKO EDTA(HIER) 
CD10 56C6 NOVOCASTRA EDTA(HEIR) 
MUM-1 MUMIP DAKO EDTA(HIER) 
BCL2 124 DAKO Citrate(HIER) 
BCL6 1B6 NOVOCASTRA EDTA(HIER) 
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Table:4  Number of DLBCL patients studied 
 
Total Number of nodal DLBCL 
185 
 
 
 
 
157 
 
 
 
 
151 
 
 
 
 
 
134 
 
 
 
 
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28cases Slide and Block not 
available or poor quality 
06 cases Disease associated 
extra-nodal site 
17casesDid not take 
treatment at CMC hospital 
11 casesDid not take 
standard chemotherapy 
17 casesFollow up less 
than six months 
106  
Total number of patients who could be evaluated in study 
Total Number of nodal DLBCL 
185 
 
 
 
PATIENTS 
Inclusion criteria: 
1. All the patients of primary nodal DLBCL disease diagnosed at CMCH will be 
taken as cases.  
2. Cases of primary nodal DLBCL who have completed 6 cycles of CHOP/R-CHOP 
chemotherapy and have a minimum of 6 months follow-up. 
3. Availability of hematoxylin and eosin stained and Immunohistochemistry slides 
from archival. 
4.All cases should be CD20 positive. 
Exclusion criteria: 
1. Transformed DLBCL, 
            2. Primaryextra-nodal 
            3. Followup less than six months 
           4. Paediatric DLBCL cases (age<15 years) 
 
 
 
 
 
 
 
 
 
 
METHODS 
Data collection 
After approval by the IRB, the patient data base at our institution were reviewed to identify 
all adults who has been diagnosed as primary nodal DLBCL and received either CHOP or 
Rituximab CHOP chemotherapy with minimum six months follow-up fromJanuary 2006 to 
April 2010. Patients who have been diagnosed earlier, their clinical data and histopathology 
paraffinblock were obtained and rreview of haematoxylin and eosin stained and 
Immunohistochemistry slides from archival material were done. Paraffin embedded, formalin 
fixed tissue blocks were used where additional IHC stains was required. The patients were 
sub-grouped as Germinal center (GCB) and non-germinal center (GCB) as per Hans 
classifier(Table:2,3).Medical information (regarding the clinical details at diagnosis,  during 
treatment, post treatment status and follow up and other co-morbidities)and blood reports, 
bone marrow aspirate and biopsy, radiological evaluation were obtained from the patients 
themselves, or review of their hospital records (laboratory reports/ physician documentation 
in hospital charts/hospital discharge summaries). Patients were stages as per Ann-Arbor 
staging system and IPI clinical scoring were done as per Shipp et al data. Patients were 
treated by either CHOP chemotherapy or Rituximab CHOP chemotherapy.Patients who did 
not get reviewed or contacted (by telephonic) in the last one year were categorised as ‘lost to 
follow up’. 
 
 
 
 
 
Chemotherapy Protocols 
 
RCHOP Chemotherapy:  
Inj Rituximab   375mg/m2     Day 1 
Inj Cyclophosphamide    800mg Day 1 
Inj Adriamycin50 mg   Day1 
InjVincristine1.4mg  Day 1 
Tab Prednisolone 60mg           Day 1-5 
 
 
CHOPChemotherapy: 
Inj Cyclophosphamide    800mg Day 1 
Inj Adriamycin50 mg   Day1 
InjVincristine1.4mg  Day 1 
Tab Prednisolone 60mg           Day 1-5 
 
                 Total six cycles of chemotherapy  repeated  every 21 days . 
 
Intrathecal Chemotherapy: Inj Methotrexate 12.5 mg with each cycle. 
 
Radiotherapy: As per the indication  , dose decision by  Deparment of 
Radiotherapy 
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Response criteria: 
 Complete response (CR):Complete resolution of all clinically and radiologically 
detectable disease, all lymphoma related symptom, and all lymphoma related 
biochemical abnormalities (like elevated LDH). Lymph nodes and nodal masses must 
regress to normal size (defined as <1.5cm for lymph node initially >1.5cm). Lymph 
nodes measuring 1.1 to 1.5cm must regress to <1cm in greatest transverse diameter, or 
by more than 75% of the sum of the perpendicular diameter (SPD). 
 Complete Response unconfirmed(CRU):The patient who fulfill criteria for 
CR with following exceptions, ie;Residual lymph node mass more than 1.5cm in 
maximum transverse diameter which have regressed more than 75% of the SPD. 
Individual node which were previously confluent must regress by more than 75% of 
the SPD compared with the size of the original mass. 
 Partial response (PR): More than 50% decrease in SPD or no increase in size of 
the other lymph node, liver or spleen. Spleneic or liver nodule must regress by at least 
50% in SPD and or appearance of new lesion. 
 Progressive Disease(PD): More than or equal to 50% increase from the nadir in 
the SPD or any previously identified abnormal node 25% in longest diameter or 
appearance of new  Lesion. 
 Stable Disease(SD):Less than PR but more than a progressive disease. 
 
 
 
 
 
IPI (International Prognostic Index) 
1. Age: more than 60 years 
2. Performance status(ECOG): of 2 or higher 
3. Serum Lactate Dehydrogenase (LDH): level 1X normal 
4. Extra-nodal sites: of 2 or more 
5. Stage: III or IV 
Staging: The Ann ArborStaging,modifiedCostwald 
Stage 1: NHL is limited to one lymph node group (e.g., neck, underarm, groin, etc.) above 
orbelow the diaphragm, or NHL is in an organ or site other than the lymph nodes (extra-
nodal) but has not spread to other organs or lymph nodes.  
Stage 2: NHL is limited to two lymph node groups on the same side of the diaphragm, or 
NHL is limited to one extra-nodal organ and has spread to one or more lymph node groups on 
the same side of the diaphragm. 
Stage 3: NHL is in two lymph node groups, with/without partial involvement of an 
extranodalorgan or site above and below the diaphragm. 
Stage 4: NHL is extensive disease,bone marrow involvement 
Additional Designations 
A - absent (no) symptoms. 
B - Presence of any of the following B symptoms: fever (greater than 101.5°), drenching 
nightsweats, unexplained weight loss of 10% or more within the last 6 months, severe itching 
. 
E -involvement of a single extranodal(other than the lymph nodes) site that directly adjoins 
or is next to the known nodal group.  
 
 
X - Presence of "bulky" disease, that is, a nodal mass whose greatest dimension is more than  
10 centimeters in size, and/ora widening of the mediastinum (middle chest) by more than  
one-third.  
Performance score: ECOG 
0.  Asymptomatic (Fully active, able to carry on all predisease activities without 
restriction) 
1. Symptomatic but completely ambulatory (Restricted in physically strenuous activity 
but ambulatory and able to carry out work of a light or sedentary nature. For example, 
light housework, office work)  
2. Symptomatic, <50% in bed during the day (Ambulatory and capable of all self care 
but unable to carry out any work activities. Up and about more than 50% of waking 
hours)  
3. Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, 
confined to bed or chair 50% or more of waking hours)  
4.  Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair)  
5. Death  
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Data analysis 
 
Statistical analyses were performed with SPSS (windows 11.01 version, SPSS inc, Chicago), 
for all variables. Descriptive statistics was calculated for all variables. Theχ2 test/ Fishers 
exact test or t-test / Mann Whitney U test was used as appropriate to compare the differences 
between groups for response to therapy. Overall survival (OS) was defined as the time from 
initiation of treatment to death or lost follow up. Event free survival (EFS) was defined as the 
time from initiation of treatment till first event or lost follow up. The event can be loss of 
response or death. The probability of OS and EFS was estimated using Kaplan-Meier 
method. For all tests, a two-sided p-value of 0.05 or less was considered statistically 
significant.  
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
Table:5 Patients Characteristics 
Patients  characteristics Total Patients
N=106(%) 
Groups  
p RCHOP n=51(%) CHOP n:55(%) 
Age, years 
       Median 
       Range 
<60 
>60 
Sex 
      Male 
      Female 
Performance Score(PF) 
    =<2 
>2 
Bone marrow involved 
B-symptom 
Bulk Disease 
Stage 
     I/II 
     III/IV 
Extra-nodal if any 
LDH 
    High(>460 u/dl) 
    Normal(<4660 u/dl) 
 
 
20-79 
78(73.6%) 
28(26.4%) 
 
71(67%) 
35(33%) 
 
75(70.8%) 
31(29.2%) 
23(21.7%) 
72(67.9%) 
21(19.8%) 
 
44(41.5%) 
62(58.5%) 
22(20.8%) 
 
80(75.5%) 
26(24.5%) 
 
53 
20-76 
38(74.5%) 
13(25.5%) 
 
35(68.6%) 
16(31.4%) 
 
36(70.6%) 
15(29.4%) 
12(23.5%) 
32(62.7%) 
8(15.7%) 
 
21(41.2%) 
30(58.5%) 
13(25.5%) 
 
37(72.5%) 
14(27.5%) 
 
48 
21-79 
40(72.7%) 
15(27.3%) 
 
36(65.5%) 
19(34.5%) 
 
39(70.9%) 
16(29.1%) 
11(20%) 
40(72.7%) 
13(23.6%) 
 
23(41.8%) 
32(58.2%) 
9(16.4%) 
 
43(78.5%) 
12(21.8%) 
 
 
 
 
1.00 
 
 
0.837 
 
 
1.00 
 
0.814 
0.303 
0.339 
 
 
1.00 
 
0.303 
 
0.652 
 
 
 
 
 
TABLE:6  Clinical and Biological Characteristics 
 Total(n:106) 
Groups 
RCHOP(n:51) CHOP(n:55)
IPI Score 
Low(0,1) 
Low Intermediate(2) 
High Intermediate(3) 
High(4,5) 
 
Low Risk(0,1,2) 
High Risk(3,4,5) 
IHC-defined subgroup 
GCB 
Non-GCB 
 
30(28.3%) 
36(33.9%) 
26(24.5%) 
14(13.2%) 
 
66(62.2%) 
40(37.7%) 
 
43(40.5%) 
63(59.4%) 
 
15(29.4%) 
17(33.3%) 
12(23.5%) 
7(13.7%) 
 
32(62.7%) 
19(37.2%) 
 
23(45%) 
28(54.9%) 
 
15(27.2%) 
19(34.5%) 
14(25.4%) 
7(12.7%) 
 
34(61.8%) 
21(38.1%) 
 
20(36.3%) 
35(59.4%) 
 
 
 
 
 
 
 
 
 
 
 
Table:7 Clinical characteristics in GCB and Non GCB subgroup 
 GCB n=43 (40.5%) Non GCB n=63 (59.5%) 
Clinical features RCHOP 
n=23 (53.5%) 
CHOP
n=20(46.5%)
p RCHOP 
n=28 (44.4%)
CHOP 
n=35 (55.6%) 
p
Age  >60 years 
<60 years 
7(30.4%) 
16(69.6%) 
5(25%)
15(75%) 
0.745 
 
6(21.4%)
22(78.6%) 
10(28.5%) 
25(71.4%) 
0.572 
 
Sex  Male 
        Female 
17(73.9%) 
6(26.1%) 
9(45%)
11(55%) 
0.068 18(64.3%)
10(35.7%) 
27(77.1%) 
8(22.8%) 
0.279 
 
Stage I,II 
         III,IV 
10(43.5%) 
13(56.5%) 
8(40%)
12(60%) 
1.00 
 
10(35.7%)
18(64.3%) 
11(31.4%) 
24(68.5%) 
0.802 
 
B-symptom Yes 
                    No 
15(65.2%) 
8(34.8%) 
15(75%)
5(25%) 
0.526 
 
17(60.7%)
11(39.3%) 
20(57.1%) 
15(42.8%) 
0.427 
 
LDH  <460 
>460 
8(34.8%) 
15(65.2%) 
7(35%)
13(65%) 
1.00 
 
6(21.4%)
22(78.6%) 
6(17.1%) 
29(82.8%) 
0.752 
 
BM   Involved 
        Not involved 
4(17.4%) 
19(82.6%) 
3(15%)
17(85%) 
1.00 
 
8(28.6%)
20(71.4%) 
6(17.1%) 
29(82.8%) 
0.772 
 
Bulk     Yes 
              No 
4(17.4%) 
19(82.6%) 
6(30%)
14(70%) 
0.473 
 
4(14.3%)
24(85.7%) 
7(20%) 
28(80%) 
0.741 
 
IPI    Low risk 
          High risk 
14(60.8%) 
9(39.1%) 
12(60%)
8(40%) 
1.00 
 
18(64.3%)
10(35.7%) 
23(65.7%) 
12(34.2%) 
1.00 
 
RT     Yes 
          No 
3(13.1%) 
20(86.9%) 
6(30%)
14(70%) 
0.263 
 
4(14.3%)
24(85.7%) 
5(14.2%) 
30(85.7%) 
1.00 
 
PF       =<2 
>2 
13(56.5%) 
10(43.5%) 
12(60%)
8(40%) 
1.00 23(82.1%)
5(17.9%) 
27(77.1%) 
8(22.9%) 
0.758 
 
Table:8 Clinical characteristics in IPI low risk and high risk subgroup 
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 IPI   Low Risk n=66,(62.3%) IPI    High Risk n=40,(37.7%)
Clinical features RCHOP  
n=32,(48.4%) 
CHOP
 n=34,(51.6%) 
p RCHOP 
n=19,(47.5%) 
CHOP 
 n=21,(52.5%) 
p
Age  >60 years 
<60 years 
5(15.6%) 
27(84.3%) 
8(23.5%)
26(76.5%) 
0.540 
 
8(42.1%)
11(57.9%) 
7(33.4%) 
14(66.6%) 
0.745 
Sex    Male 
         Female 
21(65.6%) 
11(34.4%) 
22(64.7%)
12(35.3%) 
1.00 
 
14(73.6%)
5(26.4%) 
14(66.6%) 
7(33.4%) 
0.736 
Stage   I,II 
            III,IV 
20(62.5%) 
12(37.5%) 
21(61.7%)
13(38.3%) 
1.00 
 
00(00%)
19(100%) 
2(9.5%) 
19(90.5%) 
1.00 
B-symptom Yes 
                    No 
18(56.25%) 
14(43.75%) 
23(67.6%)
11(32.4%) 
0.447 
 
14(73.6%)
5(26.4%) 
17(80.9%) 
4(19.1%) 
0.712 
LDH    <460 
>460 
12(37.5%) 
20(62.5%) 
12(35.2%)
22(64.8%) 
0.797 
 
17(89.4%)
2(10.6%) 
20(95.2%) 
01(4.8%) 
0.596 
BM    Involved 
       Not involved 
5(15.6%) 
27(84.4%) 
3(8.8%)
31(91.2%) 
0.469 
 
07(36.8%)
12(63.2%) 
8(38.0%) 
13(62.0%) 
1.00 
Bulk      Yes 
               No 
2(6.2%) 
30(93.8%) 
7(20.5%)
27(79.5%) 
0.151 
 
6(31.5%)
13(68.5%) 
6(28.5%) 
15(71.5%) 
1.00 
GCB 
Non-GCB 
14(43.7%) 
18(56.3%) 
12(35.3%)
22(64.7%) 
0.615 
 
9(47.3%)
10(52.6%) 
8(38.0%) 
13(62.0%) 
0.750 
RT    Yes 
         No 
3(9.3%) 
29(90.7%) 
5(14.7%)
29985.3%) 
0.710 
 
4(21.0%)
15(79.0%) 
6(28.5%) 
15(71.5%) 
0.721 
PF=<2 
>2 
27(84.4%) 
5(15.6%) 
27(79.4%)
7(20.6%) 
0.752 
 
9(47.4%)
10(52.6%) 
12(57.1%) 
9(42.9%) 
0.752 
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RESULTS 
Patients clinical and biological characteristics (Table:5,6,7,8) 
After applying afore mentioned inclusion and exclusion criteria, a total of 106 patients were 
included in the study. This comprises 71(67.0%) males and 35(33.0%) females with ratio 
approximately 2:1. The median age in RCHOP group was 53years (range: 20-76 years) and 
in CHOP group was 48years (range:21-79years) .Out of 106 patients 78(73.6%) patients were 
of younger age group (< 60 years) ,comprises 38(74.5%) patients in RCHOP and 40(72.7%) 
patients in CHOP group. The ECOG performance score was =<2 in 75(70.8%), the B-
symptom was present in 72(67.9%) and the bone marrow was involved in 23(21.7%) of 
patients at diagnosis. 22(20.8%) cases has one or more extra-nodal involvement and bulk 
disease (size more than 10 cm) in 21(19.8%) of patients. In 80(75.5%) of cases the LDH level 
was above the normal level (460u/dl), comprises of 37(72.5%) patients in RCHOP group and 
43(78.5%) patients in CHOP group. The haemoglobin value was <10gm% in 22(20.8%) of 
patients. CNS study was done in 29 patients and of one patients in CHOP group has 
involvement at diagnosis. As per hans .etalimmunomarkers classification the Germinal center 
B-cell like and non-germinal center B-cell like cases were 43(40.5%) and 63(59.5%) 
respectively in study population. In RCHOP group out of 51 patients, 23(45.1%) were GCB 
and 28(54.9%) patients were Non-GCB and in CHOP group out of 55 patients 20(36.3%) 
patients were GCB and 35(59.4%) patients were in Non-GCB group. All patients were scored 
as per international prognostic index. In  RCHOP group  out of 51 patients low(0,1), low 
intermediate(2), high intermediate(3) and high risks(4,5) were 15(29.4%), 17(33.3%), 
12(23.5%) and 7(13.7%) patients respectively, and in CHOP group out of 55 patients 
15(27.2%),19(34.5%),14(25.4%) and 7(12.7%) patients  respectively. Out of 106 patients 
66(62.2%) were in low risk(0,1,2) and 40(37.7%) were in high risk(3,4,5). 
 
 
In RCHOP group low risk(0,1,2),high risk(3,4,5) were 32(62.7%),19(37.2%) and CHOP 
group 34(61.8%),21(38.1%) respectively.  The patients characteristics were almost similar in 
RCHOP and CHOP groups and none of the p value were significant( significant p<0.05).The 
clinical characteristics of the patients were further analysed in two subgroups; IPI based low 
risk and high risk  groups and immune-marker based Germinal center B-cell like and Non-
germinal center B-cell like groups. The female patients 11(55%) were more compared to 
male patients 9(45%) in germinal center group patients who got CHOP chemotherapy 
(p=0.06).Other clinical characteristics distribution were similar in two groups of patients ( 
non of the p value was significant).   
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TABLE: 9 Treatment 
 Total Group  
p RCHOP CHOP 
Chemotherapy  
Radiotherapy(consolidate) 
CNS therapy(intra-thecal)* 
106
18(17.0%) 
16(15.1%)** 
51
7(13.7%) 
5(9.8%)** 
55 
11(20%) 
11(20%)** 
 
0.179 
0.445 
*At diagnosis:1(CHOP) and 0(RCHOP) had CNS disease 
**Prophylactic intrathecal therapy 
 
   TABLE:10  Post chemotherapy status RCHOP(n:51), CHOP(n:55) 
Response After 3 cycle After 6 cycle 
RCHOP CHOP p RCHOP CHOP p
Complete 
response(CR+CRU) 
Parital response(PR) 
Progressive disease(PD) 
 
32(62.7%)
19(37.3%) 
0(0%) 
24(43%)
29(%) 
2(3.6%) 
0.079 
 
 
45(88.2%)
1(1.9%) 
2(3.92%) 
3(5.88%) 
 
39(70.9%) 
6(10.9%) 
7(12.7%) 
3(5.4%) 
 
 
 
0.082 
TABLE:11 Status at last follow up (Mean follow-up 36 months) 
Response Status at last follow up 
RCHOP(n:51) CHOP(n:55) p 
Complete response(CR+CRU)
Parital response(PR) 
Progressive disease(PD) 
Stable disease(SD) 
Relapse 
37(75.2%)
0 
2(3.9%) 
2(3.9%) 
10(19.6%) 
30(54.5%) 
0 
7(12.7%) 
1(1.8%) 
17(30.9%) 
 
 
0.081 
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Table:12 Status  at the time of analysis 
GROUP Alive Dead Unknown 
Total(n:106) 
RCHOP(n:51) 
CHOP(n:55) 
71(66.9%)
37(72.5%)
34(61.8%)
20(18.9%)
7(13.7%) 
13(23.6%) 
15(14.2%) 
7(13.8%) 
8(14.6%) 
 
 
                  Table:13Unknown patient status at last follow up 
GROUP Remission Relapse Months 
(since last follow) 
Total(n:15) 
RCHOP(n:7) 
CHOP(n:8) 
8(53.3%)
7(100%) 
1(12.5%) 
7(46.6%)
0(00%) 
7(87.5%) 
 
(12-32months) 
(17-40 months) 
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Chemotherapy and response (Table:9,10,11,12,13) 
 Patients received either six cycles of CHOP chemotherapy;55(51.8%) patients or Rituximab 
with CHOP chemotherapy;51(48.2%) patients. 7(13.7%) patients in RCHOP and 11(20%) 
patients in CHOP group received consolidative radiotherapy either due to bulk disease or 
residual disease at end of six cycle of chemotherapy. Total of 16(15.1%) patients received 
prophylactic intrathecal methotrexate (5;9.8% patients in RCHOP and 11;20% patients in 
CHOP group) though only one patient had documented CNS disease in CHOP group. The 
treatment response were analysed after three cycles and six cycles as complete 
response(CR+CRu), partial response(PR),stable disease(SD),Progressive disease(PD) and 
survival were analysed as relapse free survival(RFS),event free survival(EFS) and overall 
survival(OS). After three cycles of chemotherapy the CR+CRu in CHOP was inferior 
24(43%0 vs 32(62.7%) in RCHOP group(p=0.7). After six cycle of chemotherapy  in CHOP 
group, CR+CRu, PR, PD and SD were  39(70.9%),6(10.9%),7(12.7%)and 3(5.4%) 
respectively. It was better (p=0.08) in RCHOP treatment group as the CR+Cru, PR, PD and 
SD were 45(88.2%), 1(1.9%),2(5.88%) and 3(3.92%) respectively. At the time of analysis in 
CHOP group of patients the CR+CRu was 30(54.5%),PD was 7(12.7%), SD was 1(1.8%) and 
17(30.9%) patients has relapsed. The patients treated with RCHOP, CR+CRu rate was better, 
(p=0.09) 37(75.2%) and relapse was less 10(19.6%). Out of 106 patients 71(66.9%) were 
alive, 20(18.8%) death and 15(14.3%) patients status was not known at the time of analysis. 
The subgroup analysis showed in RCHOP group 37(72.5%) alive,7(13.7%) dead and  
unknown status 7(13.7%) patients, and in CHOP group 34(61.8%)alive,13(23.6%) dead and 
unknown status 8(14.5%) patients. In analysis the unknown patients were taken as alive and 
censored at that point with the respective disease status.  
 
 
 
 
 
Survival analysis in different subgroups 
Outcome comparison of CHOP and RCHOP 
Table:14 Overall survival (OS) 
 
                    Fig: 3A Overall survival in 106 patients     
treated with CHOP and RCHOP 
Table:15 Event Free Survival(EFS) 
 
                     Fig: 3BEvent free survival  in 106 Patients 
treated with CHOP and RCHOP  
Table:16 Cummulative RFS 
 
   Fig: 3C Cumulative RFS in 106 patients  
Treated with CHOP and RCHOP 
 
 
Group 12 
months 
24 
months 
36 
months 
p 
RCHOP(n=51) 97.7% 78.4% 78.4% 0.190 
  CHOP(n=55) 86.3% 69.1% 69.1% 
Group 12 
months 
24 
months 
36 
months 
p 
RCHOP(n=51) 83.1% 73.4% 68.5% 0.190 
  CHOP(n=55) 76.2% 55.2% 47.9% 
Group 12 
months 
24 
months 
36 
months 
p 
RCHOP(n=51) 80.5% 73.4% 68.5% 0.13 
  CHOP(n=55) 77.7% 55.7% 51.1% 
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Analysis of response of  CHOP and RCHOP chemotherapy:(Table:14,15,16 
Fig:3 A,B,C) 
 
At the median follow up of 36 months the cumulative Relapse free survival was 68.1% in 
RCHOP and 51.1% in CHOP group (p=0.139). The EFS was 73.4% vs 55.2% (p=0.07) and 
OS 78.4% vs 69.1% (p=0.19) respectively in RCHOP and CHOP group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table:17 Outcome comparison in clinical  IPI risk groups(median follow up 24 months) 
IPI Risk group            OS P        EFS P   RFS  P 
Low Risk(0,1,2)  (n=66) RCHOP(n=32)      75.3%    0.26       75.1% 0.80  75.1% 0.29 
CHOP(n=34)     86.7%      72.5%  76.8%  
High Risk(3,4,5)(n=40) RCHOP(n=19)       83.3%  0.004    74.9% 0.002 74.9% 0.002 
CHOP(n=21)      41.5%      19.8%  21.1%  
Fig 4A:Overall survival in 66 IPI low risk patients with 
CHOP and RCHOP 
 
Fig 4B: Event Free survival in 66 IPI low risk patients 
with CHOP and RCHOP 
Fig 4C: Overall survival in 40 IPI  high risk patients 
with CHOP and RCHOP 
Fig 4D: Event Free Survival in 40 IPI high risk 
patients with CHOP and RCHOP 
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Analysis of response of chemotherapy in IPI risk subgroups : (Table:17 
 Fig:4 AB,C,D) 
 
In low risk group( 0,1,2) the OS, EFS and cumulative RFS at median follow-up of 24 months 
,in RCHOP group of patients  was 75.3%,75.1% and 75.1% ; and in CHOP group of patients 
was 86.7%,72.5% and 76.8% respectively( in low IPI risk group p=0.26 for OS, p=0.80 for 
EFS and p=0.29 for RFS). In highIPI risk group( 3,4,5) the OS, EFS and cumulative RFS at 
median follow-up of 24 months ,in RCHOP group of patients  was 83.3%,74.9% and 74.9% ; 
and in CHOP group of patients was 41.5%,19.8% and 21.1%% respectively( in high risk 
group was p=0.006 for OS, p=0.002 for EFS and p=0.002 for Cumulative RFS) . Patients 
who received CHOP chemotherapy the OS,EFS and RFS at median of 24 months was 
86.7%,72.5% and 76.8% in low risk and 41.5%,19.8% and 21.1% respectively in high risk 
patients( p=0.001) and in RCHOP  treated patients was 75.3%,75.1% and 75.1% in low IPI 
risk and 83.3%,74.9% and 74.9% respectively in high IPI risk patients( p=0.82) . 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome comparison GCB(n=43) and Non-GCB(n=63) groups(hans et.al) 
Table:18 GCB treated with CHOP and RCHOP(median follow up 24 months) 
 
Treatment GP OS EFS RFS
RCHOP(n:23) 89.1% 80.2% 80.2%
CHOP(n:20) 50.3% 37.3% 46.3%
p 0.06 0.02 0.16 
 
Fig 5A: Overall survival in 43GCB patients treated with CHOP and RCHOP 
 
Fig 5B: Event free survival  in 43GCB patients treated  with CHOP and RCHOP 
 
 
Fig 5C: Cumulative RFS  in 43GCB patients treated  with CHOP and RCHOP 
Fig 5(A,B,C): Addition of rituximab to CHOP chemotherapy improved OS,EFS and Cumulative RFS 
in Germinal center B-cell like subgroup of nodal DLBCL  patients. 
 
 
 
Table:19Non GCB treated with CHOP and RCHOP(median follow up of 24 months) 
 
Treatment GP OS EFS RFS
RCHOP(n:28) 69% 66.9% 66.9%
CHOP(n:35) 79.2% 60.6% 60.6%
p 0.8 0.4 0.4 
 
Fig 6A: Overall survival in 63 Non-GCB patients treated with CHOP and RCHOP 
 
Fig 6B: Event free survival  in 63Non-GCB patients treated  with CHOP and RCHOP 
 
Fig 6C: Cumulative RFS  in 63Non-GCB patients treated  with CHOP and RCHOP 
 
 
Fig 6(A,B,C): Addition of rituximab to CHOP chemotherapy improved OS,EFS and Cumulative RFS   
in Non-Germinal center B-cell like subgroup of nodal DLBCL  patients. 
 
 
Table:20 RCHOP in GCB and Non GCB(median follow up 24 months) 
 
Treatment GP OS EFS RFS 
GCB(n:23) 89.1% 80.2% 80.2% 
Non GCB(n:28) 69% 66.9% 66.9% 
p 0.3 0.8 0.8 
 
 
Fig 7A: Overall survival in 51 RCHOP treated patients  in GCB and Non-GCB subgroup. 
 
Fig 7B: Event free survival  in 51 RCHOP  treated patients in GCB and Non GCB subgroup. 
 
Fig 7C: Cumulative RFS  in 51 RCHOP treated  patients in GCB and Non GCB 
Fig 7(A,B,C): Addition of rituximab to CHOP chemotherapy improved OS,EFS and Cumulative RFS 
in Germinal center B-cell  and Non-Germinal center B-cell like subgroup of nodal DLBCL 
patients. 
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Response analysis of  chemotherapy in GCB and Non-GCB  subgroup 
(Table:18,19,20  Fig:5,6,7 A,B,C) 
The Overall survival(OS), event free survival(EFS) and cumulative relapse free 
survival(RFS)  at median follow up of 24 months   were  71.8%,58.0%,63.4% in GCB vs 
74.9%,66.3%,63.4% in non-GCB patients irrespective of different type of chemotherapy(p 
value not significant). In subgroup analysis the OS, EFS, and Cumulative RFS at median 
follow up of 24 months  in GCB group were 89.1%,80.2% and 80.2% respectively in 
RCHOP chemotherapy treated patients vs 50.3%,37.3% and 46.3% respectively in CHOP 
chemotherapy treated patients,(   OS p= 0.06,for EFS p=0.02 and for RFS p=0.16).The OS, 
EFS and Cumulative RFS  at median follow up of 24 months  in non-GCB group were 
69.%,66.9% and 66.9% respectively in RCHOP chemotherapy treated patients vs 
79.2%,60.6% and 60.6% respectively in CHOP chemotherapy treated patients,( OS 
p=0.81,for EFS p=0.41 and for RFS p=0.41).Patients who received RCHOP chemotherapy 
the OS,EFS and Cumulative RFS at median follow up of 24 months was 89.1 %,80.2% and 
80.2% in GCB and 69%%,66.9%% and 66.9% respectively in Non-GCB patients ( p value 
not significant). In CHOP treated patients the EFS and Cumulative RFS was 37.3% and 
46.3% in GCB and 60.6% each in non-GCB patients,( p value not significant). The OS was 
79.2% in non-GCB and 50.3% in GCB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table: 21 Chemotherapy related complication 
 
Complication Total no(%) RCHOP CHOP p
Neutropenia 
Hyperglycemia 
Neuropathy 
SIADH 
DVT 
61(57.5%)
26(24.5%) 
3(2.8%) 
6(5.7%) 
3(2.8%) 
35(68.6%)
14(27.5%) 
3(5.9%) 
5(9.8%) 
2(4.1%) 
26(47.3%) 
12(21.8%) 
0 
1(1.8%) 
1(1.8%) 
0.032
0.652 
0.108 
0.103 
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Chemotherapy complications(Table:21) 
Neutropenia with or without fever was the commonest chemotherapy related complication  in 
both the groups (68% in RCHOP and 47% CHOP p=0.032). The next common complication 
was hyperglycemia,(27.5% in RCHOP and 21.8% CHOP p=0.652).  followed by neuropathy 
(5.9% in RCHOP and 0% CHOP p=0.108). and SIADH (9.8% in RCHOP and 1.8% CHOP 
p=0.103). Three patients has deep vein thrombosis most probably tumor related 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
Table:22  Incidence comparison of GCBvs non GCB with 
Litrature 
Studies Total number GCB Non-GCB 
*Present 106 43(40.5%) 63(59.5%) 
**Hans,Blood 2004 152 64(42%) 88(58%) 
**Nyman,Blood2007 194 97(50%) 97(50%) 
**Kaifu JCO 2008 243 121(49.7%) 122(50.3%) 
**Shiozawa,Leuk.R2007 248 71(29%) 177(71%) 
       *Denovo DLBCL nodal site only 
       **De novo DLBCL all sites 
 
 
Table:23 Outcome comparison with Published literatures 
Studies No of patients EFS* OS*
RCHOP CHOP RCHOP CHOP RCHOP CHOP
Present study 
*at 3 years 
51                55 68.5%         47.5% 78.5%           69%
Coiffer.BNEJM2002 
*at 2 years 
202           197 61%              43% 76%              63%
GELA JCO2005 
*at 5 years 
197            202 47%                29% 58%              45%
B Columbia JCO2005 
*at  2 years 
292            292 69%               51% 78%              42%
US intergpJCO2006 
*at 5 years 
279            267 52%              35% 67%               58%
MINT trial Lancet2006 
*at 3 years 
411            413 79%              59% 93%                 84%
 
 
 
 
Discussion 
Clinical and biological characteristics 
A total of 106 patients of primary nodal diffuse large b cell lymphoma with age greater than 
15 years were included in the study. This comprises 71(67.0%) males and 35(33.0%) females 
with ratio approximately 2:12,3,4 . The median age of the patients in our study was 53 years 
(range:20-76 years) in RCHOP group and 48 years(range:21-79 years) in CHOP group of 
patients. The median age reported in major western studies is in seventh decade. The  median 
age of the group in SWOG 8516 trial ranged from 54-57 years which is comparable to our 
study1.The B-symptom was present in 72(67.9%) and the bone marrow was involved in 
23(21.7%) of patients at diagnosis. 22(20.8%) cases has one or more extra-nodal involvement 
other than the primary and bulk disease i.e greater than 10 cm on presentation in 21(19.8%) 
of patients. The published studies have quoted an incidence of 40% bulky disease and 40% 
initially confined extra-nodal disease 2,29. Our study is on primary nodal disease so the above 
finding does not correlate with literature. In our study 80(75.5%) of cases has high LDH level 
(>460u/dl) comprises of 37(72.5%) patients in RCHOP group and 43(78.5%) patients in 
CHOP group. 22(20.8%) patients presented with anemia at diagnosis (Hb<10gm%) in . The 
LDH>ULN at diagnosis ranges from 30%-57% in MInT and RECOVER 60 trial. 
In our study out of 106 patients 66(62.2%) were in low risk (0,1,2) and 
40(37.7%) were in high risk(3,4,5). In RCHOP group low risk (0,1,2),high risk (3,4,5) were 
32(62.7%),19(37.2%) and CHOP group 34(61.8%),21(38.1%) respectively. The frequency of 
IPI risk stratified groups correlates with the published data 23.  As per hans.etal immune-
markers classification (based on CD10,BCL6 and MUM1) the nodal cases were categorised  
as Germinal center B-cell like  and Non germinal center B-cell like and were 43(40.5%) and 
63(59.5%) respectively.  
 
 
In RCHOP group out of 51 patients, 23(45.1%) were GCB and 28(54.9%) 
patients were Non-GCB and in CHOP group out of 55 patients 20(36.3%) patients were GCB 
and 35(59.4%) patients were in Non-GCB group. In three major published western literature 
the frequency of distribution of GCB and Non-GCB in denovo DLBCL in all tissue  is almost 
50% in each group21,23,24(Table:22)and in asian population the published literature shows 30% 
and 70% respectively(schiozawa,leukR2007). Our study is only on nodal cases with frequency of 
distribution of GCB and Non-GCB is 40% and 60 respectively correlates nearest to hans.etal  
needs gene expression profiling for confirmation21. 
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Chemotherapy and response  
Patients received either six cycles of CHOP chemotherapy;55(51.8%) patients or Rituximab 
with CHOP chemotherapy;51(48.2%) patients. 7(13.7%) patients in RCHOP and 11(20%) 
patients in CHOP group received consolidative radiotherapy either due to bulk disease or 
residual disease at end of six cycle of chemotherapy. Total of 16(15.1%) patients received 
prophylactic intrathecal methotrexate (5;9.8% patients in RCHOP and 11;20% patients in 
CHOP group) though only one patient had documented CNS disease in CHOP group.  
After three cycles of chemotherapy the CR+Cru in CHOP was inferior 
24(43%0 vs 32(62.7%) in RCHOP group (p=0.7) though p value not significant. After six 
cycle of chemotherapy in CHOP group, CR+Cru, PR, PD and SD were  39(70.9%), 
6(10.9%), 7(12.7%)and 3(5.4%) respectively. It was better (p=0.08,) in RCHOP treatment 
group as the CR+Cru, PR, PD and SD were 45(88.2%),1(1.9%),2(5.88%) and 3(3.92%) 
respectively though the p value is not significant. At the mean follow up of 36 months the 
patients treated with RCHOP had CR+CRu  rate better 37(75.2%) and relapse was less 
10(19.6%) compared to CHOP chemotherapy(p=0.09). 
The analysis shows trend (p value not significant) towards better CR rates 
after addition of Rituximab to CHOP chemotherapy and is comparable with the literature32,33 
At the median follow up of 36 months the cumulative RFS was 73.4% in RCHOP and 55.7% 
in CHOP group (p=0.139). The EFS was 73.4% vs 55.2% (p=0.07) and OS 78.4% vs 69.1% 
(p=0.19) respectively in RCHOP and  CHOP group. The advantage of 21% in event free 
survival (EFS) and 10% in overall survival (OS) with addition of Rituximab to CHOP 
chemotherapy is comparable with the literature (Table:23). 
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In low risk IPI group( 0,1,2) the OS, EFS and cumulative RFS at median 
follow-up of 24 months ,in RCHOP group of patients  was 75.3%,75.1% and 75.1% ; and in 
CHOP group of patients was 86.7%,72.5% and 76.8% respectively( p value not 
significant).The OS is better in CHOP group most likely due poor follow up in relapse group 
of patients. In high IPI risk group( 3,4,5) the OS, EFS and cumulative RFS at median follow-
up of 24 months ,in RCHOP group of patients  was 83.3%,74.9% and 74.9% ; and in CHOP 
group of patients was 41.5%,19.8% and 21.1%% respectively(high IPI risk group p=0.006 for 
OS, p=0.002 for EFS and p=0.002 for RFS) . Patients who were treated with only CHOP 
chemotherapy did bad in high IPI risk group with  OS, EFS 41.5%,19.8% compared to low 
risk 86.7%,72.5% (p=0.001). Addition of Rituximab improves the OS, EFS 83.3%,74.9% in 
high risk comparable with the low risk 75.3%,75.1% (p=0.28).The advantage of Rituximab in 
high risk IPI  nodal DLBCL correlates with published literature 23,29,36,37.  
The Overall survival(OS), event free survival(EFS) and Cumulative relapse 
free survival(RFS)  at median follow up of 24 months  in GCB group were 89.1%,80.2% and 
80.2% respectively in RCHOP chemotherapy patients vs 50.3%,37.3% and 46.3% 
respectively in CHOP chemotherapy  patients,( OS p=0.06,for EFS p=0.02 and for RFS 
p=0.16).The survival correlates with Kai Fu JCO232008 paper which showed addition of 
Rituximab in GCB improves survival significantly.  
In non-GCB group OS,EFS and Cumulative RFS were 69.%,66.9% and 66.9% 
respectively in RCHOP chemotherapy patients vs 79.2%,60.6% and 60.6% respectively in 
CHOP chemotherapy patients,( OS p=0.81,for EFSp=0.41 and for RFS p=0.41).It does not 
correlates with literature23 and this my be  because of selection bias in this study and short 
follow-up, though there is minimal advantage in EFS and Cumulative RFS with Rituximab 
addition. Patients who received RCHOP chemotherapy the OS,EFS and Cumulative RFS at 
 
 
median follow up of 24 months was 89.1 %,80.2% and 80.2% in GCB and 69%%,66.9%% 
and 66.9% respectively in Non-GCB patients( p=0.3). Addition of Rituximab improves 
survival more in GCB than non-GCB, though p value not significant correlates with Kai Fu 
JCO232008 paper, but not with Nyman Blood24 2008 which showed addition of Rituximab 
negates the survival advantage of GCB over Non-GCB. 
Neutropenia with or without fever was the commonest chemotherapy related 
complication  in both the groups (68% in RCHOP and 47% CHOP p=0.032). The frequency 
of neutropenia in Rituximab treated patients similar to international literature32.The next 
common complication was hyperglycemia, followed by neuropathy  and SIADH . 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
Conclusion 
1) The frequency of distribution of Germinal centre(GCB) and non-Germinal 
centre(non-GCB) in nodal DLBCL cases in our population is 40% and 60% 
respectively(Table:3). 
2) The frequency of distribution of low IPI risk (0,1,2) and high IPI  risk(3,4,5) in nodal 
DLBCL cases in our population is 62% and 37.7%% respectively. 
3) Addition of Rituximab to CHOP chemotherapy improves event free survival by 20% 
and overall survival by 10% in our patients comparable to published literature (Table:14). 
4) Addition of Rituximab to CHOP chemotherapy significantly improves overall 
survival in GCB and high IPI risk group comparable to published litratures.  
5) In non-GCB and IPI low risk groups the Rituximab improves the event free survival 
and relapse free survival but not the overall survival. 
6) Neutropenia with or without fever was the most common chemotherapy related 
toxicity significantly more in Rituximab group comparable to published litratures. 
 
 
 
 
 
 
Limitation of study 
1) It is a retrospective study. 
2) Selection bias; only nodal cases with minimum six months follow up patients 
selected. 
3) DLBCL Classification based on cell of origin (GCB and non GCB) by three 
immunomarkers has its own limitations. 
4) Short follow up and follow status of the few patients at the time of analysis not 
known. 
5) Small sample size.  
 
 
 
 
 
 
 
 
PROFORMA 
 
 
 
PROFORMA: 
 
Title:Diffuse Large B cell Lymphoma Single centre study 
Sl.No: 
Name:    Hospital No:  Sex:                                Age: 
Date of diagnosis:  
At diagnosis: Haemoglobin:  Total leucocyte count:           Platelet count:     LDH:  
Viral serology (HIV, HbSAg, HCV): 
Nodal(Site):                                                            
Extranodal(Site): 
B symptoms: 
Immunomarkers 
 
 
 
Bone marrow aspirate and biopsy 
Ann Arbor staging: 
Performance score (ECOG): 
International prognostic index (score): 
Radiology: At diagnosis 
                   After three cycles of chemotherapy 
                   After six cycles of chemotherapy 
                  At follow-ups        
 
CSF examination: 
Markers CD10 BCL6 MUM1 CD20 Impression
+/-     GC/nonGC/unclassified
 
 
Chemotherapy Protocol: 
CHOP Chemotherapy  
Rituximab CHOP chemotherapy  
 
Chemotherapy cycles date: 
First cycle  
Sixth cycle  
 
Radiotherapy: 
Intrathecal CNS therapy: 
Response: 
After three cycles   
After six cycles  
At last follow up  
Relapse date and site  
 
Complication during treatment: 
Neutropenia  
Hyperglycemia  
Neuropathy  
SIADH  
Others  
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Coding for the master sheet 
 
 
 
IPI RISK GROUP 
Low Risk(0,1):1 
Low Inter(2):2 
High Inter(3):3 
High Risk(4,5):4 
 
Low Risk(0,1,2):1 
High Risk(3,4,5):2 
Hans 
GCB:1 
Non-GCB:2 
LDH 
<460U/dl:1 
>460U/dl:2 
Sex 
Male:1 
Female:2 
 
Age 
<60 years:1 
>=60 years:2 
 
B-symptom 
Yes:1 
No:1 
CNS 
Involved:1 
Not involved:2 
Not done:3 
Stage 
 I,II:1 
III,IV:2 
 
Extra-nodal  
Yes:1 
No:2 
Performance score 
=<2:1 
>:2 
Bulk disease 
Yes:1 
N:2 
 
Bone-marrow 
Involved:IN 
Not involved:NI 
 
Response to therapy 
Complete response:1 
Complete response 
unconfirmed             :1 
Partial Response:2 
Progressive disease:3 
Stable disease:4 
Relapse:5 
 
 
 
 
 
 
 
 
CHOP GROUP 
 
 
 
S.NO Age Sex Date of Dx Site involved Bulk Extranodal 
B 
symp 
Perform
ance HB CNS Bone Marrow LDH Stage IPI HANS First Cycle 
Mid 
Course 
1 31 M 1/4/2006 Cervical 2 2 1 1 13.7 2 NI 719 IIB 1 2 1/9/2006 1 
2 27 M 3/6/2006 Cervical 2 1 2 1 14.2 3 NI 978 IIIBE 3 2 3/14/2006 1 
3 30 F 4/29/2006 Cervical 1 2 1 1 7.6 3 NI 571 IIIBXS 3 1 5/4/2006 2 
4 44 M 11/24/2008 Cervical 2 2 1 1 9.9 2 NI 491 IIIB 2 2 11/28/2008 2 
5 44 M 5/31/2006 Cervical 2 1 1 3 10.6 3 NI 911 IVBE 3 1 6/17/2006 4 
6 79 M 4/28/2006 cervical 2 2 1 3 11.4 3 NI 441 IIIB 3 2 5/9/2006 1 
7 46 M 5/19/2006 Abdomen 2 2 1 2 11.8 3 NI 906 IVBS 3 2 6/9/2006 2 
8 32 M 7/4/2006 Abdomen 1 2 2 1 6.7 3 IN 898 IVBX 4 2 7/7/2006 2 
9 21 M 8/31/2005 Abdomen 1 2 1 2 8.4 3 IN 1646 IVBX 4 2 9/29/2005 2 
10 63 M 1/31/2007 Axilla 2 2 2 1 14.1 3 NI 566 IIIA 3 2 2/21/2007 1 
11 64 M 3/26/2007 inguinal 2 1 1 2 8.1 2 IN 939 IVBE 5 2 4/12/2007 2 
12 35 F 4/25/2007 Abdomen 2 2 1 1 6.8 2 NI 994 IIIBS 2 2 5/1/2007 1 
13 56 M 5/2/2007 Abdomen 2 1 1 3 12.6 2 NI 463 IIBE 3 1 5/4/2007 2 
14 61 F 7/7/2007 Abdomen 1 2 1 2 10.4 3 NI 636 IIBX 3 1 8/28/2007 2 
15 39 F 8/3/2007 Inguninal 2 2 1  1 11.7 2 NI 610 IIB 2 2 8/22/2007 1 
16 47 M 10/29/2007 Cervical 1 2 1 1 11.6 2 NI 935 IIIBX 2 2 11/3/2007 2 
17 40 M 12/20/2007 cervical 2 2 2 0 15.5 3 NI 531 IIA 1 1 1/3/2008 1 
18 48 F 15/1/2008 Cervical 2 2 1 2 5.3 3 IN 1804 IVBS 4 1 2/29/2008 2 
19 40 F 5/1/2008 Cervical 2 2 1 1 10.6 3 NI 614 IIIB 3 2 5/6/2008 1 
20 54 F 6/5/2008 Cervical 2 2 1 0 11.8 3 NI 509 IIB 1 1 7/1/2008 2 
21 52 M 6/19/2008 Cervical 1 2 1 1 12 3 NI 686 IIIBXS 2 1 7/1/2008 1 
22 66 M 6/9/2008 Inguinal 2 2 2 2 11.7 3 NI 710 IIA 2 2 6/11/2008 2 
23 62 M 9/24/2008 Cervical 1 2 1 1 7.4 3 NI 939 IIIBX 3 1 9/30/2008 2 
24 40 M 10/6/2008 Cervical 1 2 1 1 9.9 3 NI 1570 IIIBX 3 2 10/18/2008 2 
25 32 F 11/22/2008 inguinal 2 2 1 1 9.1 3 NI 2260 IVB 3 2 12/5/2008 2 
26 63 M 1/22/2009 Axilla 1 2 1 1 12.8 3 NI 664 IIBX 2 2 2/3/2009 2 
27 51 M 4/17/2009 Cervical 2 2 2 0 13.6 2 NI 556 IIA 1 2 4/29/2009 1 
ix
 
 
S.NO Date of Compleltion CNStherapy Radiotherapy 
Status post six 
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1 4/25/2006 2 2 1 2/22/2010 49.6 1 No No 49.6 1 2 2 2 2 2   
2 6/26/2006 2 2 1 5/2/2009 37.9 5 8/1/2008 Node 28.9 2 2 2 2 2 2   
3 8/29/2006 2 1 1 7/27/2007 14.9 5 4/27/2007 Node 11.9 2 2 2 2 2 2   
4 3/13/2009 2 2 3 12/17/2010 24.7 3 No No 24.7 1 2 2 2 2 2   
5 9/8/2006 2 2 4 8/14/2007 14.5 4 10/24/2006 Marrow 4.8 2 2 1 2 2 2   
6 9/8/2006 2 2 1 12/7/2007 19.3 5 3/26/2007 Node 10.9 2 2 1 1 2 2   
7 2/16/2007 2 2 1 11/22/2010 54.1 5 3/20/2007 Node 10.0 1 2 2 2 2 2   
8 11/10/2006 2 2 4 1/10/2007 6.2 4 10/11/2006 Node 3.3 2 2 1 2 2 2   
9 1/6/2006 2 1 2 10/23/2006 13.7 5 9/21/2006 Node 12.7 2 2 1 2 2 2   
10 6/6/2007 2 2 1 1/27/2009 23.9 5 8/14/2008 Node 18.4 2 2 2 2 2 2   
11 7/26/2007 2 2 2 2/12/2008 10.6 5 1/31/2008 Skin 10.2 2 2 1 1 2 2   
12 8/21/2007 2 2 1 1/11/2008 8.6 5 1/10/2008 Node 8.6 2 2 2 2 2 2   
13 11/6/2007 2 1 3 9/17/2008 16.6 4 9/17/2008 Spine 16.6 2 2 2 2 2 2   
14 12/26/2007 2 2 1 6/9/2008 11.1 5 6/9/2008 Node 11.1 2 2 1 2 2 2   
15 12/14/2007 2 2 1 9/17/2010 37.5 1 No No 37.5 1 2 2 2 2 2   
16 2/19/2008 2 2 1 8/3/2010 33.1 1 No No 33.1 1 2 2 2 2 2   
17 4/19/2008 2 2 1 12/15/2010 35.8 1 No No 35.8 1 2 2 2 2 2   
18 5/13/2008 1 1 4 7/10/2008 6.2 4 6/25/2008 Node 5.2 2 2 1 2 2 2   
19 8/22/2008 2 2 1 3/24/2010 23 1 No No 23.0 1 2 1 2 2 2   
20 12/1/2008 2 2 2 12/9/2009 18.1 5 2/25/2009 Node 8.7 1 1 2 2 2 2   
21 10/14/2008 2 1 1 10/5/2010 24.5 1 No No 24.5 1 2 2 2 2 2   
22 10/1/2008 2 2 2 1/30/2009 7.7 4 30/1/2009 No 7.7 1 1 2 2 2 2   
23 2/13/2009 2 2 1 4/13/2009 6.6 1 No No 5.6 1 1 1 2 2 2 T B 
24 2/3/2009 2 2 1 8/10/2010 22.1 1 No No 22.1 1 2 1 2 2 2   
25 3/20/2009 2 2 4 5/29/2009 6.2 5 5/29/2009 Node 6.2 1 1 2 2 2 2   
26 7/2/2009 2 2 1 2/2/2010 12.4 1 No No 12.4 1 2 1 2 2 2   
27 9/1/2009 2 1 1 8/6/2010 15.6 1 No No 15.6 1 2 2 2 2 2   
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28 60 M 6/1/2009 Cervical 2 2 1 0 10.5 3 IN 1144 IVB 4 2 6/7/2009 1 
29 45 F 7/20/2009 Cervical 2 2 2 1 11.9 3 NI 636 IIIA 2 2 7/31/2009 2 
30 34 F 11/21/2009 Cervical 2 1 1 0 11.2 3 NI 940 IIBE 2 2 12/4/2009 1 
31 68 F 12/23/2009 Cervical 2 1 1 1 12.8 3 NI 1017 IIIBE 2 1 1/11/2010 1 
32 36 M 3/31/2010 Inguinal 2 2 1 1 11.7 3 IN 980 IVB 3 2 4/2/2010 2 
33 59 M 9/14/2009 Cervical 2 2 1 1 12.4 3 IN 483 IVB 4 2 9/16/2010 2 
34 69 F 4/23/2007 Cervical 2 2 2 1 8.7 3 IN 567 IVB 4 1 5/3/2007 4 
35 33 F 3/10/2007 Abdomen 1 2 1 2 6.7 3 NI 2335 IIIBX 2 1 4/6/2007 2 
36 49 F 4/14/2007 Ingunal 1 1 1 3 6.7 3 NI 391 IIIBX 2 1 4/23/2007 2 
37 41 M 9/11/2008 Nasophyx 2 2 2 1 14.5 2 NI 490 IIA 1 2 9/26/2008 1 
38 58 M 9/4/2009 Abd flank 1 1 2 3 15.1 3 NI 2410 IIBE 2 2 9/22/2009 2 
39 63 M 3/4/2006 Ingunal 2 2 1 1 13.1 3 IN 395 IVB 2 2 3/15/2006 2 
40 61 M 1/3/2006 Nasophyx 2 2 1 1 15.5 2 NI 245 IIB 1 2 1/16/2006 2 
41 53 M 9/28/2009 Cervical 2 2 1 1 14.3 2 IN 1102 IVB 2 2 9/29/2009 2 
42 47 F 5/28/2009 Cervical 2 1 1 2 12.3 2 NI 681 IIIBE 3 1 5/29/2009 2 
43 46 M 9/15/2009 Cervical 2 1 2 2 16 2 NI 340 IIIB 2 1 9/17/2009 2 
44 22 F 10/27/2008 Tonsil 2 1 1 0 10.7 2 NI 327 IBE 0 2 11/8/2008 1 
45 39 M 11/3/2008 Tonsil 2 1 1 1 15.6 2 NI 305 IIBE 1 1 11/24/2008 1 
46 40 M 8/25/2009 Tonsil 2 1 1 1 13.7 2 NI 388 IBE 0 2 8/27/2009 1 
47 55 F 10/15/2008 Tonsil 2 1 2 1 11.5 2 NI 460 IAE 0 1 11/3/2008 1 
48 37 M 4/22/2006 Tonsil 1 1 1 2 13.8 2 NI 962 IIBX 1 2 5/1/2006 2 
49 39 F 12/4/009 Tonsil 2 1 2 0 13.7 2 NI 463 IAE 0 1 12/9/2009 1 
50 67 M 9/18/2009 Tonsil 2 1 1 1 12.8 2 NI 441 IAE 1 1 9/23/2009 1 
51 60 M 4/18/2006 Tonsil 2 1 2 1 11.5 2 NI 551 IAE 2 2 4/29/2006 1 
52 57 M 8/26/2008 Axilla 2 2 1 1 12 3 NI 553 IIIB 2 2 9/2/2008 2 
53 54 M 4/30/2007 Nasophyx 2 2 1 1 15.3 2 IN 362 IVB 1 1 5/8/2007 1 
54 53 F 1/19/2008 Nasophyx 2 2 2 1 13.1 3 NI 335 IIA 1 2 2/22/2008 1 
55 69 M 1/27/2009 Nasophyx 2 2 1 2 12.9 2 NI 971 IIB 2 2 2/28/2009 1 
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28 9/22/2009 2 2 1 11/11/2010 17.3 1 No No 17.3 1 2 2 2 2 2   
29 11/27/2009 2 2 4 3/2/2010 7.4 4 12/29/2009 Node 2.3 1 2 2 2 2 2   
30 3/23/2010 2 2 1 10/12/2010 10.7 1 No No 10.7 1 2 2 2 2 2   
31 5/10/2010 2 2 1 11/10/2010 10.6 1 No No 10.6 1 2 1 2 2 2   
32 7/30/2010 2 1 1 12/3/2010 8.1 1 No No 8.1 1 2 2 2 2 2   
33 1/7/2010 2 1 2 5/13/2010 7.9 4 2/7/2010 Node 4.8 1 2 1 2 2 2   
34 6/10/2007 2 2 4 11/13/2007 6.7 4 11/13/2007 Node 2.7 2 2 1 2 2 2   
35 7/27/2007 1 2 1 11/26/2010 44.6 1 No No 44.6 1 2 2 1 2 2   
36 9/21/2007 2 1 1 9/24/2010 41.1 1 No No 41.1 1 2 2 1 2 2   
37 3/23/2009 1 2 1 12/23/2010 27.4 1 No No 27.4 1 2 1 2 2 2   
38 1/7/2010 2 2 1 9/7/2010 12.1 1 No No 12.1 1 2 1 1 2 2   
39 7/3/2006 2 2 1 11/16/2009 44.5 1 No No 44.5 1 2 1 1 2 1   
40 10/6/2006 1 2 1 6/9/2007 17.1 1 3/16/2007 Node 14.4 2 2 1 1 2 2   
41 1/16/2010 2 2 4 3/29/2010 6 4 1/21/2010 Node 3.8 1 2 1 2 2 2   
42 9/7/2009 2 2 1 8/3/2010 14.2 5 I/27/2010 Node 8.0 1 2 1 1 2 2   
43 1/19/2010 1 2 2 3/23/2010 6.2 4 3/23/2010 Node 6.2 1 2 1 1 2 2   
44 3/7/2009 1 1 1 1/16/2010 14.7 1 No No 14.7 1 2 2 2 2 2   
45 3/5/2009 1 2 1 11/17/2010 24.4 1 No No 24.4 1 2 2 2 2 2   
46 1/8/2010 1 2 1 12/24/2010 16 1 No No 16.0 1 2 2 2 2 2   
47 3/27/2009 2 2 1 9/28/2010 23.4 1 No No 23.4 1 2 2 2 2 2   
48 9/11/2006 2 2 1 4/1/2009 35.3 1 No No 35.3 1 1 1 2 2 2   
49 4/17/2010 1 1 1 10/7/2010 10.1 1 No No 10.1 1 2 2 2 2 2   
50 2/12/2010 1 2 1 10/21/2010 13.1 1 No No 13.1 1 2 1 1 2 2   
51 8/22/2006 2 2 1 9/9/2010 52.7 1 No No 52.7 1 2 1 1 2 2   
52 1/7/2009 2 2 1 8/25/2010 24 1 No No 24.0 1 2 2 2 2 2   
53 8/22/2007 2 2 1 11/8/2008 18.3 1 No No 18.3 1 1 2 2 2 2   
54 5/22/2008 2 2 1 11/2/2010 33.4 5 11/2/2010 Node 33.4 1 2 1 2 2 2   
55 6/29/2009 1 2 1 9/15/2010 19.6 1 No No 19.6 1 2 1 1 2 2   
xii 
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1 61 M 5/12/2006 Cervical 1 2 1 1 13.1 3 NI 440 IIIAX 1 3 5/19/2006 2 
2 59 M 6/19/2006 cervical 2 1 1 1 11.7 3 IN 760 IVBE 2 2 7/17/2006 1 
3 30 M 8/2/2006 Cervical 2 1 1 2 10.3 3 IN 1974 IVBE 1 3 8/21/2006 1 
4 35 M 8/8/2006 Cervical 2 2 1 1 13.4 3 NI 420 IIB 2 1 9/5/2006 1 
5 54 M 8/24/2006 Cervical 2 2 2 1 13 3 NI 430 IIIA 1 2 9/24/2006 1 
6 37 M 9/26/2006 Cervical 1 2 1 2 13 3 NI 895 IIIBX 2 3 10/16/2006 2 
7 32 F 9/12/2006 Inguinal 2 2 2 1 11.1 3 NI 641 IIA 1 1 9/28/2006 1 
8 38 F 1/3/2007 Cervical 2 2 2 1 12.1 3 NI 381 IA 2 0 1/15/2007 1 
9 58 F 1/24/2007 Cervical 2 2 1 1 12.1 3 NI 405 IIB 2 0 3/3/2007 1 
10 64 M 3/19/2007 Cervical 2 2 2 1 12.1 3 NI 418 IIA 2 1 4/3/2007 1 
11 30 M 10/30/2007 Cervical 2 2 1 1 10.1 3 NI 420 IIIBS 1 3 11/21/2007 1 
12 56 M 4/11/2008 Cervical 2 2 1 1 13 3 NI 614 IIIBS 2 2 4/18/2008 2 
13 39 M 7/4/2008 Inguinal 2 2 1 1 14.5 3 NI 359 IIIB 1 1 7/21/2008 1 
14 71 F 7/7/2008 Cervical 2 1 2 1 10.4 3 NI 715 IIAE 2 3 7/23/2008 2 
15 67 M 12/15/2008 Cervical 2 2 1 2 9.4 3 IN 521 IVB 2 4 1/6/2009 1 
16 44 M 1/29/2009 Para-aortic 2 2 2 3 9.4 3 NI 768 IIAE 1 2 2/5/2009 2 
17 58 M 1/9/2209 Cervical 2 2 2 1 15.4 3 NI 433 IIA 1 0 1/21/2009 1 
18 57 F 3/4/2009 Cervical 2 2 2 1 13.9 3 NI 432 IIA 2 0 3/23/2009 1 
19 41 M 2/17/2009 Cervical 2 1 1 1 12.1 2 NI 831 IIIBE 2 3 3/2/2009 2 
20 47 M 2/23/2009 Iliac node 1 2 1 2 13 3 IN 647 IVB 1 4 3/13/2009 2 
21 54 F 3/13/2009 Cervical 2 2 1 1 9.5 3 NI 789 IIIBS 2 2 3/18/2009 2 
22 37 M 5/15/2009 Ingunal 2 2 1 1 14.9 3 NI 3011 IIIB 2 2 5/25/2009 1 
23 55 F 8/19/2009 Axillary 2 2 1 1 11 3 IN 1051 IVB 2 2 8/25/2009 1 
24 43 M 10/19/2009 Axillary 2 2 1 1 12.5 3 IN 718 IVB 2 2 11/2/2009 2 
25 60 F 10/20/2009 Inguinal 2 2 1 3 12.6 3 IN 1612 IVB 1 4 11/2/2009 2 
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1 9/14/2006 2 1 1 2/25/2008 21.5 1 No 21.5 2 1 1 1 2 2  
2 11/3/2006 2 2 1 11/20/2007 17.1 5 2/23/2007 8.2 2 2 1 2 2 2  
3 12/6/2006 2 2 1 7/9/2010 47.2 5 7/13/2007 11.3 1 2 1 2 1 2  
4 12/21/2006 2 2 1 9/26/2008 25.6 1 No 25.6 2 1 2 2 2 2  
5 1/8/2007 2 2 1 11/22/2010 51 1 No 51 1 2 2 1 2 2  
6 1/27/2007 2 2 1 8/5/2010 46.3 1 No 46.3 1 2 1 2 2 2  
7 1/21/2007 2 2 1 6/15/2009 33.1 1 No 33.1 1 2 2 2 2 2  
8 5/7/2007 2 2 1 8/28/2009 31.8 1 No 31.8 1 2 2 2 2 2  
9 6/20/2006 2 2 1 7/7/2008 17.4 5 12/19/2007 10.8 2 2 1 2 2 2  
10 7/27/2007 2 2 1 3/28/2008 12.3 5 2/20/2008 11.1 2 2 1 2 2 2  
11 4/18/2008 2 2 1 11/4/2008 12.2 1 No 12.2 2 2 2 2 2 2  
12 9/23/2008 2 2 1 8/20/2010 28.3 1 No 28.3 1 2 1 2 2 4  
13 11/4/2008 2 2 1 12/9/2010 29.2 1 No 29.2 1 2 1 2 2 2  
14 11/23/2008 2 2 1 1/27/2009 6.7 1 No 6.7 1 2 2 1 2 2  
15 7/3/2009 2 2 1 7/9/2010 18.8 1 No 18.8 1 2 1 1 2 2  
16 5/21/2009 2 1 1 11/27/2010 24 1 No 24 1 2 1 2 2 2  
17 5/19/2009 2 2 1 12/28/2010 23.6 1 No 23.6 1 2 2 2 2 2  
18 7/10/2009 2 2 1 1/22/2010 10 1 No 10 1 2 2 2 2 2  
19 7/16/2009 1 1 1 10/21/2010 20.1 1 No 20.1 1 2 1 2 1 2  
20 6/26/2009 2 2 2 9/22/2010 18.9 3 No 18.9 1 2 1 2 2 2 DVT 
21 6/30/2009 2 2 1 8/3/2010 16.7 1 No 16.7 1 2 2 2 2 2  
22 9/15/2009 2 2 1 12/24/2010 19.3 1 No 19.3 1 2 2 2 2 2  
23 12/8/2009 2 2 1 9/14/2010 12.8 1 No 12.8 1 2 1 2 2 2  
24 5/12/2010 2 1 1 9/24/2010 11.2 1 No 11.2 1 2 1 2 2 2  
25 1/29/2010 2 2 4 5/19/2010 6.9 4 1/29/2010 4 1 2 1 2 2 2 DVT 
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26 53 M 12/9/2009 Cervical 2 1 2 1 10.7 2 IN 415 IVAE 2 2 12/9/2009 1 
27 60 F 12/14/2009 Cervical 1 1 2 1 10.6 3 NI 2614 IIAXE 2 2 22/12/2009 2 
28 52 M 3/19/2010 Axillary 2 2 1 1 13.1 3 NI 339 IIIB 1 1 3/25/2010 2 
29 54 F 10/6/2009 Cervical 2 2 1 2 9 3 IN 662 IIB 2 2 10/19/2009 1 
30 22 M 2/18/2009 Cervical 2 1 1 2 12 3 IN 978 IVBE 1 3 2/28/2009 1 
31 53 M 3/9/2007 Inguinal 2 2 2 1 7.2 3 IN 683 IVAE 2 3 3/19/2007 1 
32 43 M 10/9/2007 cervical 2 1 2 1 13.1 3 NI 766 IIAE 2 2 10/10/2007 1 
33 34 M 2/20/2008 Axillary 2 2 1 1 10.3 3 NI 489 IB 2 1 2/27/2008 1 
34 48 M 9/5/2007 cervical 2 2 1 1 10.9 2 NI 1080 IIIBS 2 2 9/16/2007 1 
35 53 M 3/13/2010 Mediastinal 2 1 2 2 14.9 3 NI 2885 IIIAE 2 4 3/23/2010 1 
36 37 F 4/31/2007 Para-aortic 2 2 1 1 9.4 3 NI 749 IIIBS 1 2 5/1/2007 1 
37 36 M 3/31/2010 Inguinal 1 2 1 1 11.7 3 IN 780 IVB 2 3 4/15/2010 1 
38 69 F 11/22/2007 Mesentric mass 2 2 1 2 14.1 3 NI 473 IIIAS 1 4 30/11/2007 2 
39 45 F 1/7/2010 Cervical 2 2 2 1 12.2 3 NI 483 IA 1 1 1/23/2010 1 
40 42 F 1/25/2010 Retroperitonium 1 1 1 1 9.4 3 NI 1339 IIIBEX 2 3 2/10/2010 2 
41 62 M 1/3/2008 Vertbra 2 1 2 2 13.1 2 NI 826 IVAES 2 4 1/14/2008 2 
42 64 F 7/28/2006 Axilla 2 1 1 1 6.7 2 NI 787 IIIBE 2 4 8/15/2006 1 
43 61 M 7/4/2007 Abdomen 2 2 1 1 15.2 3 NI 703 IIB 1 2 7/10/2007 2 
44 72 M 6/11/2009 Cervical 2 2 1 2 14.1 3 NI 582 IIB 1 2 6/18/2009 1 
45 20 M 1/27/2009 Cervical 2 2 2 0 14.7 3 NI 487 IIA 2 0 2/5/2009 1 
46 56 M 1/23/2010 Cervical 1 2 1 2 13.6 3 NI 2457 IIIBX 1 3 2/1/2010 2 
47 63 M 12/5/2008 Tonsil 2 1 2 1 13.7 2 NI 800 IIIAE 1 3 1/6/2009 1 
48 29 M 11/16/2007 Tonsil 2 1 2 1 17.2 3 NI 414 IAE 1 0 11/19/2007 1 
49 26 F 10/5/2007 Nasophyx 2 1 2 1 12.7 2 NI 552 IIAE 1 1 10/10/2007 2 
50 76 M 1/3/2007 Retroperitonium 1 2 1 2 
12.4 3 NI 959 IIBX 1 2 1/11/2007 2 
51 51 M 5/30/2009 Cervical 2 2 1 3 8.7 3 NI 388 IB 1 0 6/3/2009 1 
xv
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26 3/26/2010 1 2 1 10/8/2010 10 1 No 10 1 2 2 1 2 2 2 
27 4/13/2010 2 2 4 6/18/2010 6.1 4 5/18/2010 5.1 1 2 2 21 2 2 2 
28 7/13/2010 2 2 3 11/9/2010 7.7 3 No 7.7 1 2 2 1 2 2 2 
29 2/12/2010 2 2 1 9/3/2010 10.9 1 No 10.9 1 2 2 1 1 2 2 
30 7/3/2009 2 2 1 5/28/2010 15.2 1 No 15.2 1 2 2 1 2 2 2 
31 8/27/2007 2 2 1 6/15/2009 27.2 1 No 27.2 1 2 2 2 1 2 2 
32 2/12/2008 1 2 1 7/26/2010 33.5 1 No 33.5 1 2 2 1 2 2 2 
33 6/10/2008 2 2 1 10/1/2010 31.3 1 No 31.3 1 2 2 2 2 2 2 
34 1/4/2008 2 2 1 11/24/2008 14.7 5 5/10/2008 8.1 2 1 2 1 2 2 2 
35 7/6/2010 2 2 1 11/9/2010 7.9 1 No 7.9 1 2 2 1 2 2 2 
36 8/17/2007 2 2 1 6/8/2008 13.3 5 11/27/2007 6.9 2 1 2 1 2 2 2 
37 7/30/2010 2 1 1 12/3/2010 8.1 1 No 8.1 1 2 2 2 2 2 2 
38 4/23/2008 2 2 1 12/23/2010 37 5 1/25/2010 26.1 1 2 2 1 2 2 2 
39 8/5/2010 2 2 1 12/3/2010 10.8 1 No 10.8 1 2 2 2 2 2 2 
40 5/28/2010 2 2 3 10/7/2010 8.4 3 No 8.4 1 2 2 1 2 2 2 
41 4/9/2008 2 1 1 10/26/2010 33.7 5 9/15/2009 20.4 1 2 2 1 1 2 2 
42 12/1/2006 2 2 1 7/22/2008 28.7 5 12/31/2007 22 2 1 2 1 1 1 1 
43 11/7/2007 2 2 3 3/15/2008 8.4 5 12/6/2007 5.1 2 1 2 1 1 2 2 
44 9/29/2010 2 2 1 11/23/2010 17.4 1 No 17.4 1 2 2 1 1 2 1 
45 6/3/2009 2 2 1 8/27/2010 19 1 No 19 1 2 2 2 2 2 2 
46 6/12/2010 2 2 1 9/24/2010 8 1 No 8 1 2 2 1 1 2 2 
47 5/6/2009 1 2 1 9/15/2009 9.3 1 No 9.3 1 2 2 1 1 2 1 
48 3/19/2008 2 2 1 9/14/2010 33.9 1 No 33.9 1 2 2 2 2 2 2 
49 2/13/2008 1 1 1 3/23/2010 29.6 1 No 29.6 1 2 2 1 2 2 2 
50 5/4/2007 2 2 1 4/21/2009 27.6 1 No 27.6 1 2 2 1 1 2 2 
51 10/22/2009 2 2 1 10/14/2010 16.5 1 No 16.6 1 2 2 1 1 2 1 
 
xvi
